In the period from 2013 to 2023, the insulin in dosage market in Germany exhibited a general downward trend, with the value decreasing from 3.6673 billion US dollars to 2.4906 billion US dollars in 2023. Significant year-on-year variations were observed, particularly notable declines in 2014 (-6.84%), 2015 (-7.34%), 2016 (-7.92%), and 2022 (-11.47%). However, there was a notable increase in 2019 (+14.9%). The five-year CAGR from 2018 to 2023 stood at -0.27%. Forecasts from 2024 to 2028 indicate a continued decline, with the market size expected to reach 2.1539 billion US dollars by 2028, reflecting a five-year CAGR of -2.42% and an overall projected growth rate of -11.55% over the next five years.
Future trends to watch for:
- Continued downward pressure on market values due to pricing regulations and competitive market dynamics.
- Potential impact of emerging biosimilar products increasing market competition.
- Advancements in diabetes care technology and alternative therapies influencing market demand.
- Policy changes and healthcare reforms potentially affecting market landscape.
